Shares of Chemours (CC) are soaring 5.54% in pre-market trading on Wednesday following the company's impressive second-quarter earnings report released late Tuesday. The chemical company significantly outperformed analyst expectations, demonstrating robust financial performance amid challenging market conditions.

Chemours reported adjusted earnings of $0.58 per diluted share for Q2, a substantial increase from $0.38 in the same period last year and comfortably beating the FactSet analyst consensus of $0.46. The company's sales for the quarter ended June 30 reached $1.62 billion, up from $1.55 billion a year earlier and surpassing analyst projections of $1.57 billion.

Looking ahead, Chemours provided guidance for the third quarter and full year 2025. For Q3, the company expects a slight sequential decrease in consolidated net sales of 4% to 6%, with consolidated adjusted EBITDA projected to range between $175 million and $195 million. For the full year 2025, Chemours anticipates sales between $5.9 billion and $6 billion, slightly above the current FactSet analyst consensus of $5.88 billion. This positive outlook, combined with the strong Q2 results, appears to be fueling investor optimism and driving the stock's pre-market surge.